Aflac (AFL) Projected to Post Earnings on Wednesday

Aflac (NYSE:AFL) will likely be posting its quarterly earnings results after the market closes on Wednesday, February 5th. Analysts expect Aflac to post earnings of $1.63 per share and revenue of $4.16 billion for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Aflac Stock Down 0.7 %

Shares of NYSE:AFL opened at $106.65 on Tuesday. The business has a fifty day simple moving average of $105.50 and a 200 day simple moving average of $106.55. Aflac has a 12-month low of $75.44 and a 12-month high of $115.50. The firm has a market cap of $59.25 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.16 and a beta of 0.99. The company has a quick ratio of 0.08, a current ratio of 0.08 and a debt-to-equity ratio of 0.32.

Aflac Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Wednesday, February 19th will be given a $0.58 dividend. The ex-dividend date is Wednesday, February 19th. This represents a $2.32 annualized dividend and a yield of 2.18%. This is an increase from Aflac’s previous quarterly dividend of $0.50. Aflac’s dividend payout ratio (DPR) is presently 30.12%.

Insider Activity

In other Aflac news, EVP Audrey B. Tillman sold 24,744 shares of the firm’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $103.40, for a total transaction of $2,558,529.60. Following the completion of the transaction, the executive vice president now owns 222,618 shares in the company, valued at $23,018,701.20. This trade represents a 10.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on AFL shares. Barclays boosted their target price on Aflac from $96.00 to $98.00 and gave the stock an “underweight” rating in a research report on Monday, January 6th. Keefe, Bruyette & Woods lowered their price objective on shares of Aflac from $108.00 to $107.00 and set a “market perform” rating for the company in a research note on Friday, January 10th. StockNews.com raised shares of Aflac from a “sell” rating to a “hold” rating in a research note on Wednesday, January 8th. Evercore ISI decreased their target price on shares of Aflac from $104.00 to $102.00 and set an “underperform” rating for the company in a research note on Wednesday, December 4th. Finally, BMO Capital Markets initiated coverage on shares of Aflac in a report on Thursday, January 23rd. They issued a “market perform” rating and a $111.00 target price for the company. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $103.71.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.